

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

RPP decision paper

Review of TA311; Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation

Final recommendation post consultation
The guidance should be transferred to the 'static guidance list'

1. Background

This guidance was issued in April 2014.

At the Guidance Executive (GE) meeting of 7 February 2017 it was agreed that we would consult on the recommendations made in the GE proposal paper. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

2. Proposal put to consultees and commentators

The guidance should be transferred to the 'static guidance list'.

3. Rationale for selecting this proposal

No new evidence or ongoing research has been identified that is likely to alter the conclusions of the guidance (that is, lead to a change in clinical and cost effectiveness of treatment).

4. Summary of consultee and commentator responses

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

<p>Respondent: MSD</p> <p>Response to proposal: No comment</p> <p>No comment via NICE docs</p>	<p>Comment from Technology Appraisals</p> <p>Thank you</p>
<p>Respondent: Janssen</p> <p>Response to proposal: No comment</p> <p>We agree with NICE that there is no new evidence that is likely to alter the conclusions of guidance TA311. Therefore, we welcome the decision from NICE to move TA311 to the static list.</p>	<p>Comment from Technology Appraisals</p> <p>Thank you</p>
<p>Respondent: Pfizer</p> <p>Response to proposal: No comment</p> <p>No comment via NICE docs</p>	<p>Comment from Technology Appraisals</p> <p>Thank you</p>
<p>Respondent: Royal College of Pathologists</p> <p>Response to proposal: No comment</p> <p>No comment via NICE docs</p>	<p>Comment from Technology Appraisals</p> <p>Thank you</p>

Paper signed off by: Jenniffer Prescott, 31 March 2017

Contributors to this paper:

Technical Lead: Abi Senthinathan

Technical Adviser: Martyn Burke

Project Manager: Samantha Shannon